+++
Thrombotic Microangiopathy
++
The role of caplacizumab in the treatment of thrombotic thrombocytopenic purpura remains controversial given its high cost and limited benefit, despite its inclusion in 2020 guidelines.
++
Careful monitoring of the ADAMTS-13 activity and inhibitor status and use of rituximab can prevent dangerous relapses.